The telomeric region of repetitive DNA sequences at the end of chromosomes prevents end-to-end fusion of chromosome terminals and deterioration of the doublestrand free ends. Because of the 'endreplication problem', telomeres shorten with each round of cell division, resulting in cell senescence. The enzyme telomerase compensates for telomere shortening by elongating telomeric sequences, thereby prolonging the lifespan of the cell. Studies of articular cartilage and bone tissues have indicated that telomere shortening limits normal cell function and proliferation, while the telomere maintenance mechanisms of osteosarcoma cells facilitate escape from cell death and promote immortality. This article reviews the literature on this topic and provides an extensive discussion of the basic molecular biology and roles of telomeres and telomerase in musculoskeletal diseases such as osteoarthritis, osteoporosis and osteosarcoma. Findings to date suggest that telomeres and telomerase may become novel therapeutic targets for the diagnosis, treatment and prevention of musculoskeletal disorders.
Introduction
It has long been known that normal human somatic cells have a finite lifespan. They survive a limited number of cell cycles, after which the apoptotic molecular process is irreversibly initiated. This phenomenon, first described by Hayflick in fibroblasts, 1,2 is currently referred to as the Hayflick limit. It was subsequently proposed that this limited replicative lifespan is a result of the progressive shortening of telomeres. 3, 4 The existence of the telomere was first suggested by Müller in 1938. 5 Telomeres are highly conserved sequences at the ends of chromosomes, forming a kind of cap and playing a critical role in maintaining the integrity of the genome. They consist of a large number of tandem repeats of the nucleotide sequence TTAGGG and have been identified in humans and other vertebrates. 6 Telomeres are believed to shorten with each round of replication by approximately 50 -200 base pairs (bp). 4 After 30 -40 cell divisions, the telomeres reach a critically short length and lose the ability to divide further, a phenomenon known as replicative senescence. 7 This has been demonstrated not only in human fibroblasts, 7 lymphocytes 8 a D Li and Q Yuan contributed equally to this article. D Li, Q Yuan, W Wang Telomeres in musculoskeletal diseases and keratinocytes, 9 but also in chondrocytes 10 and bone. 11 In contrast, stem cells and malignant cell lines divide indefinitely with passage in culture, and this property of immortality is facilitated by telomere maintenance mechanisms that overcome telomere shortening. 12, 13 One of these mechanisms is telomerase activation, which can elongate the telomere sequence using its RNA template. 14, 15 However, telomerase is not present in approximately 10% of human tumours, with a higher percentage in some types of sarcoma. These cells use the mechanism known as alternative lengthening of telomeres (ALT) to maintain telomere length. 16 Many human disorders not associated with tumours have also been shown to be related to telomere or telomerase dysfunction. This review discusses the basic molecular biology of telomeres and telomerase and their roles in human musculoskeletal diseases, such as osteoarthritis, osteoporosis and osteosarcoma.
Literature search
The PubMed database was searched for all articles up to December 2011 using the following search terms: telomere, telomerase, osteoarthritis, chondrocytes, osteoporosis, osteoblast and osteosarcoma. Articles published in English were selected for review based on their relevance to the role of telomeres or telomerase in osteoarthritis, osteoporosis and osteosarcoma.
Telomeres and telomerase structures and functions
Telomeres cap the ends of chromosomes, preventing end-to-end fusion and the DNA damage that would occur if the free ends of the DNA molecule were processed as doublestranded breaks. 17 Although the tertiary and quaternary structures of telomeres vary among species, they share numerous copies of G-rich DNA repeats and associated proteins in the primary and secondary structures. In mammals, such as humans, the telomere repeat element is composed of an extensively reiterated TTAGGG oligonucleotide unit that does not encode any gene product; 6 however, the end of the telomere is a single-strand 3′ G-rich overhang of about 150 bp. This overhang avoids recognition as a double-stranded break and subsequent activation of the conventional DNA repair mechanism by invading the telomeric double helix and forming two internal loops, the D-loop and the T-loop, with the participation of the shelterin complex. 18, 19 The shelterin complex consists of six proteins, comprising telomeric repeat-binding factors 1 and 2 (TRF1 and TRF2, respectively), TRF1-interacting nuclear factor 2 (TIN2), repressor activator protein 1 (Rap1), TIN2-interacting protein 1 (TINT1, also called TPP1) and protection of telomeres 1 protein (POT1), which play different roles. TRF1 and TRF2 bind specifically to doublestranded TTAGGG repeats and POT1 binds to the 3′ G-rich overhang. The three remaining factors, TIN2, Rap1 and TINT1, interact with the telomere-bound proteins to form a complex that allows cells to distinguish telomeres from sites of DNA damage. 20, 21 Telomeres act to maintain the integrity of chromosomes; however 100 -200 bp of telomeric DNA sequence is lost each time the cell divides because of the 'end replication problem'. When the telomeric DNA strand becomes too short to form loops, the chromosome loses its endpoint protection. 22 Telomerase counters this erosion of telomeres by catalysing the addition of TTAGGG nucleotide repeats to the 3′ terminus of the chromosome's DNA. 23 The telomerase holoenzyme consists of two essential D Li, Q Yuan, W Wang Telomeres in musculoskeletal diseases components: telomerase reverse transcriptase (TERT) and the telomerase RNA component (TERC). TERT is generally taken to be the rate-limiting component of telomerase activity and it adds a TTAGGG nucleotide repeat to the 3′ end of the telomere's leading strand by using TERC as a template. 24 In contrast to TERT, which has been relatively conserved throughout evolution, TERC varies greatly among species. 25 In humans, TERC contains 451 nucleotides, including an 11 nucleotide template and several conserved regions. 24, 26 It has been suggested that TERC not only provides the template for the synthesis of telomere DNA repeats but also plays essential roles in catalysis, accumulation of telomerase ribonucleoprotein, TERC 3′-end processing, localization and holoenzyme assembly. 25 Other protein factors, such as the ribonucleoproteins dyskerin, GAR1, NHP2 and NOP10, are also assembled in the telomerase complex and play distinctive roles in telomerase function. 27 
Telomeres and musculoskeletal disorders
Telomeric erosion, maintenance and repair are important processes in the determination of cell fate. Telomere shortening induces apoptosis and senescence, causing premature ageing and other pathophysiological conditions; however, cells can exploit the telomere maintenance mechanism to avoid senescence and become immortal, which is considered a major step in carcinogenesis. 28 It has been suggested that telomeres and telomerase are associated with the pathogenesis of several different diseases, including various musculoskeletal diseases. 29 Musculoskeletal diseases are among the most common human afflictions. They affect all age groups and frequently cause disability, impairment and handicaps that severely affect quality of life and can lead to life-threatening conditions. The most frequent symptoms are pain or discomfort in the bones, joints, muscles or related tissues, and these symptoms are associated with substantial medical and economic burdens on healthcare systems and society. 30 The roles of telomeres and telomerase in relation to some highly prevalent musculoskeletal diseases -osteoarthritis, osteoporosis and osteosarcoma -are discussed in the following sections.
Telomeres and osteoarthritis
The degenerative joint disease osteoarthritis is the most common type of chronic musculoskeletal disease and a major cause of joint disability in elderly people. The incidence of osteoarthritis has been estimated to increase from two-to 10-fold between 30 and 65 years of age, and continues to increase thereafter. Ageing is strongly associated with an increased risk of osteoarthritis. 31 As a type of quiescent cell, the chondrocyte lacks a self-renewal function; its senescence decreases its capacity for maintenance and repair, leading to decreases in the size and aggregation of proteoglycan aggrecans and loss of matrix tensile strength and stiffness, both of which are known to accelerate the development of osteoarthritis. 32 The telomere length of peripheral blood leucocytes (PBLs) is considered a potential biomarker of biological ageing. 33 Like other age-related diseases, osteoarthritis is closely related to reduced telomere length in PBLs. Zhai et al. 34 reported that leucocyte telomeres in female patients with hand osteoarthritis were significantly shorter (by 178 bp) than those in healthy females with normal radiographs. A similar finding was observed D Li, Q Yuan, W Wang Telomeres in musculoskeletal diseases for telomeres in human osteoarthritic chondrocytes; 35 however, in both control subjects and patients with osteoarthritis, the telomeres in chondrocytes were longer than those in PBLs. There was no significant difference in telomere length between groups stratified by sex and age; however, the telomeres of chondrocytes from patients with osteoarthritis were 20 -25% shorter than in those from control subjects.
The degenerative progression of osteoarthritis may be closely related to oxidative stress, and reactive oxygen species (ROS) may play an important role in this progression. 36 ROS are free radical byproducts generated by the normal cellular metabolism of oxygen, and include the hydroxyl radical, superoxide anion and hypochlorite ion, as well as molecular oxygen-derived nonradical species such as hydrogen peroxide. 37 ROS mediate both beneficial and deleterious processes in mammals. When cellular antioxidant capacity is insufficient to neutralize excessive ROS, the balance is tipped towards a harmful outcome. There is evidence that the telomere shortening found in chondrocytes may be caused by ROS-mediated DNA damage; in human chondrocytes, ROS has been shown to induce telomere instability and result in replicative senescence and dysfunction. 38, 39 Obesity and trauma increase the mechanical stresses on joints and excessive loading of articular surfaces can cause incongruity or malalignment which may, subsequently, increase the release of ROS and accelerate telomere erosion. 40, 41 Several studies have focused on the question of whether telomerase may be useful as a target in attempts to maintain telomere length and delay the progression of chondrocyte senescence. One study showed that human TERT (hTERT) transduction was not sufficient to extend the lifespan of a normal chondrocyte population under typical monolayer culture conditions. 42 Chondrocytes of patients with osteoarthritis, however, were responsive to retroviral transduction of exogenous telomerase, exhibiting increased lifespan. 43 Similar results were achieved with canine chondrocytes, in which exogenous hTERT expression not only extended lifespan but also resulted in downregulation of matrix metalloproteinase 1. 44 These results highlight the potential of gene therapy for treating osteoarthritis.
Telomeres and osteoporosis
Osteoporosis is a skeletal disease characterized by systemic impairment of bone mass and microarchitecture. It increases the risk of fracture and accounts for a large proportion of healthcare-associated costs in the elderly and situations involving limited quality of life. 45 Stable bone mass maintenance depends on a balance between bone-forming osteoblasts and boneresorbing osteoclasts. Besides the metabolic pathogenic processes of osteoporosis, agerelated cell senescence is considered to play an important role. Osteoblast telomeres lose about 100 bp per population doubling, which is similar to rates of loss found in other human somatic cell types, 46 but it has been suggested that telomere length is significantly shorter in osteoporosis. Low bone mineral density (BMD) is the primary characteristic of osteoporosis. In a study by Bekaert et al., 47 110 samples from healthy males aged 71 -86 years were assessed by restriction fragment length analysis of telomeres. Although age-adjusted mean telomere restriction fragment length was not correlated with baseline BMD, it was associated with longitudinal bone loss for different distal forearm sites. In 2150 female patients with osteoporosis, reduced leucocyte D Li, Q Yuan, W Wang Telomeres in musculoskeletal diseases telomere length was independently associated with a decrease in BMD and the presence of osteoporosis. 48 This correlation was more significant than in some other musculoskeletal diseases, such as rheumatoid arthritis. 49 Thus, telomere length has been suggested as a possible predictive biomarker of osteoporosis. In contrast, other studies have found telomere length not to be associated with BMD, osteoporosis or fracture in older adults. 50, 51 This seemingly contradictory finding may merely reflect the different populations studied and the different methods used to measure telomere length.
Since telomerase deficiency can lead to age-related bone loss by decreasing bone formation and increasing bone resorption, 52 attempts have been made to use telomerase as a new therapeutic target in the treatment of osteoporosis. Transfection of the gene encoding hTERT into human telomerasenegative osteoblastic cells produced efficient telomerase activity in these cells, resulting in increased telomere length and continued activity for more than 30 population doublings, in contrast to untransfected telomerase-negative control cells which exhibited telomere shortening and senescence after only 10 -15 population doublings. 53 Another study showed that incubating hTERT-transfected osteoblastic cells with human bone fragments promoted bone mineral content and increased BMD of the bone fragments. 54 Mesenchymal stem cells (MSCs) are the major skeletal stem cells from which osteoblastic cells are derived and enhancing the differentiation of MSCs to osteoblastic cells may accelerate osteogenesis and compensate for age-related bone loss. Telomerase was able to extend the lifespan of MSCs and enhance their bone-forming capability by accelerating osteogenic differentiation. 55 Some drugs, such as the compound TA-65, derived from an extract of the commonly used traditional Chinese medicinal plant Astragalus membranaceus, may lower the risk of osteoporosis by acting as a telomerase activator. 56
Telomeres and osteosarcoma
Two telomere maintenance mechanisms have been identified in human tumours: one is telomerase activity and the other is ALT. Most carcinoma cells use telomerase activity to maintain telomere function. 57 Approximately 90% of tumours, including a large proportion of squamous cell carcinomas, express telomerase. 58 Telomerase activation is indispensable for the carcinogenesis of some osteosarcomas, especially the process of metastasis. 59 -61 Yu et al. 62 found that hTERT-transfected osteosarcoma cells exhibited strong proliferative ability, suggesting that telomerase-mediated telomere maintenance is able to promote the invasive ability of tumour cells. Although > 80% of all carcinomas rely on telomerase activity to maintain stable telomere length, many types of sarcoma show telomere elongation in a manner that is consistent with ALT. 63 Osteosarcomas are common sarcomas that mostly affect adolescents. The ALT pathway is the predominant mechanism for maintaining telomere function in certain osteosarcomas. 59 Henson et al. 64 detected ALT-associated promyelocytic leukaemia bodies by combining promyelocytic leukaemia immunofluorescence with telomere fluorescence in situ hybridization. They reported that ALT occurred in 47% of osteosarcomas, especially those in younger patients. In contrast to Ewing's sarcoma, in which most tumour samples show evidence of telomerase activity, osteosarcoma shows a D Li, Q Yuan, W Wang Telomeres in musculoskeletal diseases much higher prevalence of ALT. 65 The telomerase and ALT mechanisms of telomere maintenance have been considered landmarks of tumour progression and patient prognosis in osteosarcomas. Tomoda et al. 66 found that the level of hTERT mRNA expression was a useful marker for evaluating the clinical aggressiveness of soft tissue tumours, and that the frequency of telomerase activity in sarcomas with distant metastasis was significantly greater than that in locally recurrent sarcomas. Moreover, telomerase expression has been detected more often in highly malignant tumours than in low-grade sarcomas, suggesting that telomerase activation is a late event in sarcoma progression. 67, 68 Telomerase expression has been shown to be predictive of an unfavourable outcome in osteosarcoma. A study of patients with TERTpositive osteosarcoma revealed that their overall survival rate was poor in comparison with patients who were TERT-negative. 60 Patients without activated telomerase activity and ALT had a much lower mortality rate than other patients. 59 Correlation between the risk of osteosarcoma and telomere length has also been reported. A pilot study suggested that females with short telomeres and who secrete more oestrogen, which in turn promotes hTERT gene expression, may be at increased risk of osteosarcoma. 69 By exploiting the telomerase and ALT mechanisms, cancer cells acquire the ability to bypass senescence and become immortal. Telomerase is considered a highly attractive and relatively safe therapeutic target for cancer therapy. 70 Hyperthermia was shown to inhibit telomerase activity in osteosarcoma cells. Although this downregulation was reversible, it also provided a possible new adjuvant strategy to treat osteosarcoma. 71 Some drugs, such as suramin and cationic porphyrin 5,10,15,20tetra-(N-methyl-4-pyridyl)porphyrin, have been characterized as telomerase inhibitors and are being investigated as therapeutic agents in patients with osteosarcoma who are resistant to chemotherapy. 72, 73 Virotherapy is emerging as a promising alternative form of tumour therapy. Telomerase-specific oncolytic adenovirus has been shown to suppress the growth of osteosarcoma cells significantly both in vitro and in vivo. 74, 75 Telomeres have also been considered as a manipulative tool for delaying the progression of osteosarcoma. The natural phenol resveratrol, for example, can induce senescence-like growth inhibition of osteosarcoma cells associated with the instability of telomeric DNA. 76 
Conclusions
Many studies have indicated that telomeres and telomerase are closely linked to a number of human diseases. Besides musculoskeletal disorders and tumours, several age-related diseases, such as atherosclerosis, diabetes and heart failure, have been associated with shortened telomere length. 77 
